FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029123929> ?p ?o ?g. }

• W2029123929 endingPage "126" @default.
• W2029123929 startingPage "121" @default.
• W2029123929 abstract "Increases in body weight gain are important, and clinically significant adverse effects of several antiepileptic drugs (AED) including valproate and gabapentin. Weight gain may contribute to medication non-compliance, discontinuation, and importantly, may have secondary medical implications as well. Levetiracetam (LEV) is indicated for adjunctive treatment of partial seizures. The objective of the present evaluation was to examine the effects of LEV treatment on body weight in adult patients.We analyzed data derived from four prospective, placebo-controlled randomized, clinical trials conducted in both in the US and Europe. Patients included in the present analysis were both men and women, greater than 16 years old, and who had LEV exposure for at least 1 month. Body weight was measured at baseline and at the final LEV study visit. Data are analyzed for all patients, by gender, body mass index (BMI), duration of LEV exposure and by concomitant AED treatment. Wilcoxan Signed Rank, or Rank Sum test used where appropriate, with significance assigned at P<0.05. Data are presented as mean values+/-1 S.D.Nine-hundred and seventy patients (age=37.5 years, 54% men/46% women) were evaluated. There were no significant differences in baseline demographics between LEV (n=631) or placebo (n=339) treated patient groups. Mean LEV dose and duration of treatment were 2053 mg/day (maximum dose of 4000 mg/day) and 125 days (maximum=181 days), respectively. Concomitant AED therapy included CBZ, PHT, VPA, PB, GBP, LTG, and VGB. For LEV-treated patients, no significant changes in body weight were noted. Mean body weight at baseline versus final study visit for LEV was 74.3+/-16.6 kg and 74.3+/-16.6 kg, respectively. For placebo-treated patients, baseline versus end of treatment weight was 72.4+/-15.4 kg and 72.7+/-15.9 kg, respectively, representing a slight, yet clinically trivial increase. Clinically significant weight change as defined as >7% change from baseline weight, occurred in 9% of LEV-treated patients (4.5% had increase in weight/4.5% decrease) versus 9.4% (5.9% had increase/3.5% decrease) in placebo-treated patients. Weight changes were not significantly different between groups. Neither baseline BMI, gender, or background AEDs, appeared to predispose to significant weight change for LEV-treated patients.We conclude that treatment with LEV at clinically relevant dosages is not associated with significant weight change. LEV would, therefore, appear to be a weight neutral AED." @default.
• W2029123929 created "2016-06-24" @default.
• W2029123929 creator A5007823967 @default.
• W2029123929 creator A5042974562 @default.
• W2029123929 creator A5060793900 @default.
• W2029123929 creator A5087537519 @default.
• W2029123929 date "2003-10-01" @default.
• W2029123929 modified "2023-10-10" @default.
• W2029123929 title "Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials" @default.
• W2029123929 cites W1966103593 @default.
• W2029123929 cites W1976885468 @default.
• W2029123929 cites W2013331040 @default.
• W2029123929 cites W2014261444 @default.
• W2029123929 cites W2014306890 @default.
• W2029123929 cites W2015918699 @default.
• W2029123929 cites W2022933598 @default.
• W2029123929 cites W2023162470 @default.
• W2029123929 cites W2029639141 @default.
• W2029123929 cites W2033393696 @default.
• W2029123929 cites W2050359523 @default.
• W2029123929 cites W2067753412 @default.
• W2029123929 cites W2082093102 @default.
• W2029123929 cites W2084929535 @default.
• W2029123929 cites W2090357050 @default.
• W2029123929 cites W2091776412 @default.
• W2029123929 cites W2099686832 @default.
• W2029123929 cites W2120557435 @default.
• W2029123929 cites W2131454803 @default.
• W2029123929 cites W2139454197 @default.
• W2029123929 cites W2140131270 @default.
• W2029123929 cites W2141344427 @default.
• W2029123929 cites W2159341874 @default.
• W2029123929 cites W2357554713 @default.
• W2029123929 cites W2916596946 @default.
• W2029123929 cites W4256330632 @default.
• W2029123929 doi "https://doi.org/10.1016/j.eplepsyres.2003.08.009" @default.
• W2029123929 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14642996" @default.
• W2029123929 hasPublicationYear "2003" @default.
• W2029123929 type Work @default.
• W2029123929 sameAs 2029123929 @default.
• W2029123929 citedByCount "36" @default.
• W2029123929 countsByYear W20291239292012 @default.
• W2029123929 countsByYear W20291239292013 @default.
• W2029123929 countsByYear W20291239292014 @default.
• W2029123929 countsByYear W20291239292016 @default.
• W2029123929 countsByYear W20291239292018 @default.
• W2029123929 countsByYear W20291239292019 @default.
• W2029123929 countsByYear W20291239292020 @default.
• W2029123929 countsByYear W20291239292021 @default.
• W2029123929 countsByYear W20291239292023 @default.
• W2029123929 crossrefType "journal-article" @default.
• W2029123929 hasAuthorship W2029123929A5007823967 @default.
• W2029123929 hasAuthorship W2029123929A5042974562 @default.
• W2029123929 hasAuthorship W2029123929A5060793900 @default.
• W2029123929 hasAuthorship W2029123929A5087537519 @default.
• W2029123929 hasConcept C118552586 @default.
• W2029123929 hasConcept C126322002 @default.
• W2029123929 hasConcept C142724271 @default.
• W2029123929 hasConcept C147583825 @default.
• W2029123929 hasConcept C168563851 @default.
• W2029123929 hasConcept C187212893 @default.
• W2029123929 hasConcept C197934379 @default.
• W2029123929 hasConcept C204787440 @default.
• W2029123929 hasConcept C27081682 @default.
• W2029123929 hasConcept C2775858608 @default.
• W2029123929 hasConcept C2777332695 @default.
• W2029123929 hasConcept C2778186239 @default.
• W2029123929 hasConcept C2778715236 @default.
• W2029123929 hasConcept C2779384505 @default.
• W2029123929 hasConcept C2780221984 @default.
• W2029123929 hasConcept C2780320433 @default.
• W2029123929 hasConcept C42219234 @default.
• W2029123929 hasConcept C71924100 @default.
• W2029123929 hasConceptScore W2029123929C118552586 @default.
• W2029123929 hasConceptScore W2029123929C126322002 @default.
• W2029123929 hasConceptScore W2029123929C142724271 @default.
• W2029123929 hasConceptScore W2029123929C147583825 @default.
• W2029123929 hasConceptScore W2029123929C168563851 @default.
• W2029123929 hasConceptScore W2029123929C187212893 @default.
• W2029123929 hasConceptScore W2029123929C197934379 @default.
• W2029123929 hasConceptScore W2029123929C204787440 @default.
• W2029123929 hasConceptScore W2029123929C27081682 @default.
• W2029123929 hasConceptScore W2029123929C2775858608 @default.
• W2029123929 hasConceptScore W2029123929C2777332695 @default.
• W2029123929 hasConceptScore W2029123929C2778186239 @default.
• W2029123929 hasConceptScore W2029123929C2778715236 @default.
• W2029123929 hasConceptScore W2029123929C2779384505 @default.
• W2029123929 hasConceptScore W2029123929C2780221984 @default.
• W2029123929 hasConceptScore W2029123929C2780320433 @default.
• W2029123929 hasConceptScore W2029123929C42219234 @default.
• W2029123929 hasConceptScore W2029123929C71924100 @default.
• W2029123929 hasIssue "2-3" @default.
• W2029123929 hasLocation W20291239291 @default.
• W2029123929 hasLocation W20291239292 @default.
• W2029123929 hasOpenAccess W2029123929 @default.
• W2029123929 hasPrimaryLocation W20291239291 @default.
• W2029123929 hasRelatedWork W1571312040 @default.
• W2029123929 hasRelatedWork W1973658753 @default.

• next